Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
Cancer Res Treat. 2023;55(1):112-122. Published online July 19, 2022
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.
Materials and Methods Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.
Results A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.
Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.
Citations
Citations to this article as recorded by
The importance of re-biopsy in the era of molecular therapy for lung cancer Nensi Lalic, Daliborka Bursac, Marko Bojovic, Marko Nemet, Ivan Ergelasev Srpski arhiv za celokupno lekarstvo.2024; 152(3-4): 209. CrossRef
Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi Pathology.2024; 56(5): 653. CrossRef
Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim Thoracic Cancer.2024; 15(19): 1513. CrossRef
Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control Ha-Lim Jeon, Meesong Kwak, Sohee Kim, Hye-Yeon Yu, Ju-Young Shin, Hyun Ae Jung Scientific Reports.2024;[Epub] CrossRef
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations Eunbin Kwag, Soo-Dam Kim, Seong-Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa-Seung Yoo Integrative Cancer Therapies.2024;[Epub] CrossRef
Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer Eun Hye Lee, Se Hyun Kwak, Kyeong Yeon Kim, Chi Young Kim, Sang Hoon Lee, Seok-Jae Heo, Yoon Soo Chang, Eun Young Kim Frontiers in Oncology.2024;[Epub] CrossRef
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study Qing Zhou, He-Long Zhang, Li-Yan Jiang, Yuan-Kai Shi, Yuan Chen, Jin-Ming Yu, Cai-Cun Zhou, Yong He, Yan-Ping Hu, Zong-An Liang, Yue-Yin Pan, Wen-Lei Zhuo, Yong Song, Gang Wu, Gong-Yan Chen, You Lu, Cui-Ying Zhang, Yi-Ping Zhang, Ying Cheng, Shun Lu, Chan Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10771. CrossRef
Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA.
Materials and Methods Patients with activating EGFR mutations in their tumor DNA underwent screening with ctDNA analysis using Mutyper and Cobas v2 assays. Enrolled subjects received osimertinib 80 mg, once daily. Primary endpoint was objective response rate (ORR) and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety.
Results Among 39 screened patients, 29 were ctDNA positive for activating EGFR mutations and 19 were enrolled (ex19del, n=11; L858R/L861Q, n=7; G719A, n=1). Median age was 70 and most patients had brain metastases (15/19, 79%). ctDNA test sensitivity for activating EGFR mutations was 74% using both methods and 62% (Mutyper) or 64% (Cobas v2) for individual methods. ORR was 68% (13/19), median PFS was 11.1 months (95% confidence interval [CI], 0.0 to 26.7), and median DoR was 17.6 months (95% CI, 3.5 to 31.7). ORR and median PFS were significantly superior with ex19del (91%; 21.9 months; 95% CI, 5.5 to 38.3) than with L858R/L861Q (43%; 5.1 months; 95% CI, 2.3 to 7.9). One patient discontinued the drug because of drug-related interstitial pneumonitis.
Conclusion Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA.
Citations
Citations to this article as recorded by
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro Expert Opinion on Emerging Drugs.2024; 29(2): 139. CrossRef
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, John Fernando Montenegro Palacios, Yamil Liscano Cancers.2024; 16(13): 2338. CrossRef
ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer Bin Liu, Bingtian Zhao, Yan Yin, Yan Jiang, Xue Feng, Lei Wang, Liang Zhai, Guangxin Liu, Dongsheng Shi, Jianwen Qin Cancer Management and Research.2024; Volume 16: 1405. CrossRef
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang Journal of Clinical Medicine.2023; 12(4): 1438. CrossRef
Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana-Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris A. Charalambous, Amanda Psyrri, Emily Tsaroucha, Ioannis Boukovinas, Anna Koumarianou, Dora Hatzidaki, Evi Lianidou, Vassilis Georgouli Cancers.2022; 14(6): 1574. CrossRef
Purpose
Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) harboring the T790M resistance mutation, detected from circulating tumor DNA (ctDNA) with unknown tumor mutation status.
Materials and Methods
To extract ctDNA from plasma, 15 mL of peripheral blood was withdrawn and centrifuged immediately before storage. Cobas ver. 2 and PANA Mutyper were used for ctDNA genotyping. Patients with T790M, detected from ctDNA, were enrolled and they received a oncedaily administration of osimertinib 80 mg. The primary endpoint was objective response rate (ORR), and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety.
Results
Eighty patients with acquired resistance to prior EGFR-TKI therapies were screened. ctDNA of 21 patients showed T790M positivity, and 19 patients were enrolled. In the responseevaluable population (n=15), ORR was 66.7% (10/15). Median PFS was 8.3 months (95% confidence interval [CI], 7.9 to 8.7) and median DoR was 6.8 months (95% CI, 5.3 to 8.3) in the intent-to-treat population (n=19). No subject experienced drug-related adverse event of grades ≥ 3 or required dose reduction. The sensitivity of the ctDNA tests was 56.8% using both methods and 45.9% with either method from the estimated T790M-positive cases.
Conclusion
Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy.
Citations
Citations to this article as recorded by
CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses Hao Lou, Zelai Wu, Guangyou Wei Oncology Reports.2024;[Epub] CrossRef
Liquid biopsy for the management of NSCLC patients under osimertinib treatment Aliki Ntzifa, Theodoros Marras, Vasilis Georgoulias, Evi Lianidou Critical Reviews in Clinical Laboratory Sciences.2024; 61(5): 347. CrossRef
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis Liuxian Guo, Guojin Zhou, Min Huang, Kejing Tang, Jing Xu, Jie Chen The Clinical Respiratory Journal.2024;[Epub] CrossRef
A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers Qixuan Li, Tianyi Wang, Yijie Tang, Xian Zou, Zhongqi Shen, Zixin Tang, Youlang Zhou, Jiahai Shi Cancer Cell International.2024;[Epub] CrossRef
Deciphering Dormant Cells of Lung Adenocarcinoma: Prognostic Insights from O-glycosylation-Related Tumor Dormancy Genes Using Machine Learning Chenfei Dong, Yang Liu, Suli Chong, Jiayue Zeng, Ziming Bian, Xiaoming Chen, Sairong Fan International Journal of Molecular Sciences.2024; 25(17): 9502. CrossRef
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC? Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang Journal of Clinical Medicine.2023; 12(4): 1438. CrossRef
Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma Gujie Wu, Qin Hu, Hongyu Chen, Min He, Huiyun Ma, Lin Zhou, Kun Xu, Hefei Ren, Juntao Qi Frontiers in Oncology.2023;[Epub] CrossRef
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies Xuezheng Sun, Page Abrahamson, Nicholas Ballew, Linda Kalilani, Kelesitse Phiri, Kelly F. Bell, Alexander Slowley, Magdalena Zajac, Erin Hofstatter, Alexander Stojadinovic, Angela Silvestro, Zebin Wang, Amine Aziez, Solange Peters Cancer Investigation.2023; 41(6): 571. CrossRef
Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer Liu Xin, Yang Yue, Ren Zihan, Cui Youbin, Lu Tianyu, Wang Rui Frontiers in Physiology.2023;[Epub] CrossRef
Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer Woo Kyung Ryu, Seung Hyun Yong, Sang Hoon Lee, Hye Ran Gwon, Hye Ryun Kim, Min Hee Hong, Go Eun Oh, Sehee Jung, Chi Young Kim, Yoon Soo Chang, Eun Young Kim Lung Cancer.2023; 186: 107390. CrossRef
Current treatment of non-small cells lung cancer with EGFR mutation: first-line and management upon progression Sergio Sandiego Contreras, Lucía Morales López, Reyes Claramunt Alonso, Javier Lavernia Giner, Ignacio Gil Bazo Revisiones en Cáncer.2023;[Epub] CrossRef
A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma Huan Wang, Yueli Shi, Xia Xu, Shumin Xu, Yuting Shi, Weiyu Chen, Kai Wang Annals of Medicine.2023;[Epub] CrossRef
Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer Jiaqi Zhu, Yun Jiang, Tianyi Wang, Anqi Wu, Tingting Zhou, Anping Zhang, Yijie Tang, Zihao Shen, Jinjie Wang, Hao Zhou, Jiahai Shi, Jianle Chen, Ihtisham Bukhari Disease Markers.2022; 2022: 1. CrossRef
The potential of liquid biopsy in the management of cancer patients A. Markou, E. Tzanikou, E. Lianidou Seminars in Cancer Biology.2022; 84: 69. CrossRef
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges Miguel García-Pardo, Maisam Makarem, Janice J. N. Li, Deirdre Kelly, Natasha B. Leighl British Journal of Cancer.2022; 127(4): 592. CrossRef
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies Hyunkoo Kang, Haksoo Lee, Dahye Kim, Byeongsoo Kim, JiHoon Kang, Hae Yu Kim, HyeSook Youn, BuHyun Youn Biomedicines.2022; 10(6): 1308. CrossRef
Identification of molecular subtypes, risk signature, and immune landscape mediated by necroptosis-related genes in non-small cell lung cancer Jiaqi Zhu, Jinjie Wang, Tianyi Wang, Hao Zhou, Mingming Xu, Jiliang Zha, Chen Feng, Zihao Shen, Yun Jiang, Jianle Chen Frontiers in Oncology.2022;[Epub] CrossRef
Sotorasib and other drugs comparison in treating non-small cell lung cancer Yueting Ren Highlights in Science, Engineering and Technology.2022; 8: 675. CrossRef
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion Yeon Joo Kim, Won Jun Ji, Jae-Cheol Lee, Sung-Min Chun, Chang-Min Choi Cancer Research and Treatment.2022; 54(4): 985. CrossRef
Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer Xiaoxu Fang, Shaokun Yu, Yingying Jiang, Yan Xiang, Kaihua Lu Frontiers in Oncology.2022;[Epub] CrossRef
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim Thoracic Cancer.2021; 12(4): 444. CrossRef
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1 Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim Cancer Research and Treatment.2021; 53(1): 93. CrossRef
Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database Chundi Gao, Jing Zhuang, Huayao Li, Cun Liu, Chao Zhou, Lijuan Liu, Fubin Feng, Changgang Sun Aging.2021; 13(3): 3957. CrossRef
Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis Yingji Chen, Longyu Jin, Zhibin Jiang, Suo Liu, Wei Feng Frontiers in Oncology.2021;[Epub] CrossRef
PIWI‐interacting RNAs are aberrantly expressed and may serve as novel biomarkers for diagnosis of lung adenocarcinoma Juan Li, Nan Wang, Fang Zhang, Shan Jin, Yaqi Dong, Xiangjun Dong, Yuqing Chen, Xue Kong, Yao Tong, Qi Mi, Yinghui Zhao, Yi Zhang Thoracic Cancer.2021; 12(18): 2468. CrossRef
Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment Hao Zhou, Miaosen Zheng, Muqi Shi, Jinjie Wang, Zhanghao Huang, Haijian Zhang, Youlang Zhou, Jiahai Shi BMC Cancer.2021;[Epub] CrossRef
Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma Weiju Zhang, Sumei Yao, Hua Huang, Hao Zhou, Haomiao Zhou, Qishuang Wei, Tingting Bian, Hui Sun, Xiaoli Li, Jianguo Zhang, Yifei Liu OncoImmunology.2021;[Epub] CrossRef
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC Bin Qiu, Wei Guo, Fan Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, Hua Bao, Yang Xu, Yang Shao, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He Nature Communications.2021;[Epub] CrossRef
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs Zhenli Diao, Yanxi Han, Rui Zhang, Jinming Li Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2020; 1873(2): 188363. CrossRef
Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC Stefanie Mayer, Gerlinde Schmidtke-Schrezenmeier, Christian Buske, Frank G. Rücker, Thomas F.E. Barth, Peter Möller, Ralf Marienfeld Cancers.2020; 12(7): 1917. CrossRef
Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples Yanqin Huang, Jiayi Mu, Lina Qi, Weiting Ge, Xuefeng Fang, Yongmao Song, Ying Yuan, Shu Zheng Clinical Chemistry and Laboratory Medicine (CCLM).2020; 58(9): 1451. CrossRef
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer Jing Liu, Xuemei Li, Yinghong Shao, Xiyun Guo, Jinggui He Medicine.2020; 99(34): e21826. CrossRef
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin Ryan Woodhouse, Meijuan Li, Jason Hughes, David Delfosse, Joel Skoletsky, Pei Ma, Wei Meng, Ninad Dewal, Coren Milbury, Travis Clark, Amy Donahue, Dan Stover, Mark Kennedy, Jennifer Dacpano-Komansky, Christine Burns, Christine Vietz, Brian Alexander, Prit PLOS ONE.2020; 15(9): e0237802. CrossRef
Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response Rui-Yu Li, Zhi-Yong Liang Chinese Medical Journal.2020; 133(20): 2476. CrossRef
Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode Zhou Jiawei, Mu Min, Xing Yingru, Zhang Xin, Li Danting, Liu Yafeng, Xie Jun, Hu Wangfa, Zhang Lijun, Wu Jing, Hu Dong Frontiers in Molecular Biosciences.2020;[Epub] CrossRef
Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer Kelly C.S. Oliveira, Iago Barroso Ramos, Jessica M.C. Silva, Williams Fernandes Barra, Gregory J. Riggins, Vikrant Palande, Catarina Torres Pinho, Milana Frenkel-Morgenstern, Sidney E.B. Santos, Paulo P. Assumpcao, Rommel R. Burbano, Danielle Queiroz Calc Molecular Cancer Research.2020; 18(4): 517. CrossRef
Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer Young-Woo Kim, Young-Ho Kim, Yura Song, Han-Seong Kim, Hye Won Sim, Shiv Poojan, Bang Wool Eom, Myeong-Cherl Kook, Jungnam Joo, Kyeong-Man Hong Experimental & Molecular Medicine.2019; 51(8): 1. CrossRef
Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer Lei Huang, Hao Huang, Xiao-Ping Zhou, Jin-Feng Liu, Chun-Rong Li, Min Fang, Jun-Rong Wu Medicine.2019; 98(43): e17705. CrossRef
Purpose Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS. Materials and Methods This is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib, or erlotinib) as first line treatment.
Results Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS–; n=2, PNA–/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS– cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS– group. Conclusion PNA clamping showed a significantly higher detection rate of EGFR gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.
Citations
Citations to this article as recorded by
Highly Sensitive Enrichment of Low-Frequency Variants by Hairpin Competition Amplification Zhaocheng Liu, Rui Zhang, Xixi Jiang, Li Ji, Ping Sun, Yong Ji, Yu Zhang, Yan Ding, Koukou Li, Zhening Pu, Fengsheng Zhou, Jian Zou Analytical Chemistry.2023; 95(32): 12015. CrossRef
Peptide Nucleic Acids: Recent Developments in the Synthesis and Backbone Modifications Gurpreet Singh, Vikramdeep Monga Bioorganic Chemistry.2023; 141: 106860. CrossRef
Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection Hwa Park, Yoo Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh Cancers.2023; 15(23): 5679. CrossRef
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim Thoracic Cancer.2021; 12(10): 1598. CrossRef
Bronchial brushing cytology is comparable to bronchial biopsy for epidermal growth factor receptor mutation test in non-small cell lung cancer Joo-Yeon Koo, Nah-Ihm Kim, Taebum Lee, Yoo-Duk Choi Cytojournal.2020; 17: 16. CrossRef
Potential applications of peptide nucleic acid in biomedical domain Kshitij RB Singh, Parikipandla Sridevi, Ravindra Pratap Singh Engineering Reports.2020;[Epub] CrossRef
Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients Insu Kim, Jung Seop Eom, Eun Jung Jo, Jeongha Mok.Ki Uk, Kwangha Lee, Ki Uk Kim, Hye‐Kyung Park, Min Ki Lee, Mi‐Hyun Kim Thoracic Cancer.2019; 10(7): 1561. CrossRef
Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR Xiao-Dong Ren, Ding-Yuan Liu, Hai-Qin Guo, Liu Wang, Na Zhao, Ning Su, Kun Wei, Sai Ren, Xue-Mei Qu, Xiao-Tian Dai, Qing Huang Scientific Reports.2019;[Epub] CrossRef
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis Jae-Uk Song, Jonghoo Lee Yonsei Medical Journal.2018; 59(2): 211. CrossRef
Comparative analysis of Adam33 mutations in murine lung cancer cell lines by droplet digital PCR, real-time PCR and Insight Onco™ NGS Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim Molecular & Cellular Toxicology.2018; 14(2): 221. CrossRef
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer Tae‐Ok Kim, In‐Jae Oh, Bo Gun Kho, Ha Young Park, Jin Sun Chang, Cheol‐Kyu Park, Hong‐Joon Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi Thoracic Cancer.2018; 9(7): 856. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review Kyung-Taek Rim Toxicology and Environmental Health Sciences.2018; 10(3): 147. CrossRef
Molecular masquerading of rare EGFR L858M/L861R mutations as common L858R/L861Q mutations by PNA clamping assay Ji Hyung Hong, Seung-Hyun Jung, Min Sung Kim, Sug Hyung Lee, Yeun-Jun Chung Pathology.2017; 49(4): 453. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Peptide nucleic acids: Advanced tools for biomedical applications Anjali Gupta, Anuradha Mishra, Nidhi Puri Journal of Biotechnology.2017; 259: 148. CrossRef
Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim Cancer Biomarkers.2017; 20(4): 477. CrossRef
Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis Roberta D’Agata, Maria Giuffrida, Giuseppe Spoto Molecules.2017; 22(11): 1951. CrossRef
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing Mi-Young Park, Min Hee Jung, Eun Young Eo, Seokjoong Kim, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Jin Haeng Chung, Cheol Hyeon Kim, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee Oncotarget.2017; 8(22): 36331. CrossRef
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism Christopher S Hong, Chunzhang Yang, Zhengping Zhuang Molecular Therapy - Nucleic Acids.2016; 5: e314. CrossRef
Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response Ha Young Park, Hyung Joo Oh, Ki‐Hyun Kim, Tae‐Ok Kim, Cheol‐Kyu Park, Hong‐Jun Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, In‐Jae Oh, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi Thoracic Cancer.2016; 7(6): 639. CrossRef
Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations Wei Jie Seow, Keitaro Matsuo, Chao Agnes Hsiung, Kouya Shiraishi, Minsun Song, Hee Nam Kim, Maria Pik Wong, Yun-Chul Hong, H. Dean Hosgood, Zhaoming Wang, I-Shou Chang, Jiu-Cun Wang, Nilanjan Chatterjee, Margaret Tucker, Hu Wei, Tetsuya Mitsudomi, Wei Zhe Human Molecular Genetics.2016; : ddw414. CrossRef